GENERAL ATLANTIC, L.P.

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1017645
Institutional-grade research for retail investors
Email me the moment this fund files its next 13F

13F Reported Value

$2.9B

Holdings

12

Latest Filing

2026-06-30

Filing Quarter

Q2 2026

Portfolio Overview

GENERAL ATLANTIC, L.P. disclosed 12 positions worth $2.9B in its Form 13F-HR for Q2 2026, led by $LFTO (Liftoff Mobile, Inc.) at 20.9% of the equity portfolio, followed by $DLO and $CHYM. During the quarter the fund opened 3 new positions and exited 3 — including a new stake in $LFTO and a full exit from $EWCZ. The portfolio is most concentrated in Technology (33.0% of disclosed assets). All figures are sourced directly from GENERAL ATLANTIC, L.P.’s Form 13F-HR filing with the SEC under CIK 1017645.

Sector Allocation

TechnologyFinancialsIndustrialsHealthcareConsumer Discretionary

AUM History

Top Equity Holdings by Value

Quarterly Activity — Q2 2026

Click any card to unlock

Top Holdings

AI Quality Scored

Unlock AI quality scores for every holding

32-signal composite ranking on each of GENERAL ATLANTIC, L.P.'s 12 positions.

Showing top 10 of 12 holdings.

Sector Allocation

Technology

$959.2M

Financials

$769.8M

Industrials

$633.1M

Healthcare

$541.7M

Consumer Discretionary

$3.1M

Full HoldingsGENERAL ATLANTIC, L.P. (Q2 2026)

All 12 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.

TickerCompanyValue
LFTO$LFTOLiftoff Mobile, Inc.$608.1M
DLO$DLOdLocal Ltd$606.3M
CHYM$CHYMChime Financial, Inc.$435.4M
ALKT$ALKTALKAMI TECHNOLOGY, INC.$351.1M
XP$XPXP Inc.$334.4M
PHVS$PHVSPharvaris N.V.$226.5M
SPTX$SPTXSeaport Therapeutics, Inc.$132.5M
NRIX$NRIXNurix Therapeutics, Inc.$73.6M
RVMD$RVMDRevolution Medicines, Inc.$67.0M
PBLS$PBLSParabilis Medicines, Inc.$42.1M
RSKD$RSKDRISKIFIED LTD.$26.8M
GROV$GROVGrove Collaborative Holdings, Inc.$3.1M

New Positions (3)

LFTO$LFTO Liftoff Mobile, Inc.$608.1M
SPTX$SPTX Seaport Therapeutics, Inc.$132.5M
PBLS$PBLS Parabilis Medicines, Inc.$42.1M

Exited Positions (3)

EWCZ$EWCZ European Wax Center, Inc.
CNTA$CNTA Centessa Pharmaceuticals plc
BULL$BULL Webull Corp

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

to search all 8,700+ institutional filers.

Available Analysis

13F Pro tracks comprehensive institutional data for GENERAL ATLANTIC, L.P. including:

Full 13F portfolio with all holdings
Quarter-over-quarter position changes
Accumulation & distribution patterns
Sector allocation breakdown
Historical portfolio evolution
New positions & complete exits
Concentration analysis
Peer comparison with similar funds
AI-powered portfolio insights

Track GENERAL ATLANTIC, L.P.'s Full Portfolio

See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for GENERAL ATLANTIC, L.P. and 8,700+ other institutional investors.

View Pricing

Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

AI-Powered Hedge Fund Analysis: GENERAL ATLANTIC, L.P.

13F Pro is an AI hedge fund tracker and stock research platform. For GENERAL ATLANTIC, L.P. (SEC CIK: 1017645), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in GENERAL ATLANTIC, L.P.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.